Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06158841 · ClinicalTrials.gov registry record · Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
- 20
- Study locations
NCT06158841 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by AbbVie. The registered enrollment target is 380 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06158841, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world. In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Pomalidomide
- DRUG Carfilzomib
- DRUG Elotuzumab
- DRUG Etentamig
Study Locations (20)
California
- Alta Bates Summit Medical Center for Research /ID# 261438 - Berkeley
- Providence - St. Jude Medical Center /ID# 262031 - Fullerton
- VA Loma Linda Healthcare System /ID# 261015 - Loma Linda
- Cedars-Sinai Medical Center /ID# 261008 - Los Angeles
Illinois
- University of Illinois Hospital and Health Sciences System /ID# 246349 - Chicago
- Rush University Medical Center /ID# 265690 - Chicago
- Nancy W. Knowles Cancer Center /ID# 271361 - Elmhurst
- Springfield Clinic - First /ID# 262266 - Springfield
Florida
- Mayo Clinic Hospital Jacksonville /ID# 263324 - Jacksonville
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230 - Jacksonville
Massachusetts
- Beth Israel Deaconess Medical Center /ID# 271535 - Boston
- Dana-Farber Cancer Institute /ID# 261554 - Boston
Michigan
- Regents of the University of Michigan /ID# 261577 - Ann Arbor
- Karmanos Cancer Institute - Detroit /ID# 266298 - Detroit
Alabama
- University of Alabama at Birmingham - Main /ID# 261434 - Birmingham
Arizona
- Mayo Clinic Hospital - Phoenix /ID# 263326 - Phoenix
Colorado
- Rocky Mountain Cancer Centers - Lone Tree /ID# 278320 - Lone Tree
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2024-05-19 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06158841
The ClinicalTrials.gov registry entry for NCT06158841 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (30% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Selinexor is the first listed.
NCT06158841 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT06158841 about?
NCT06158841 is a clinical study titled "Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma". Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed...
What is the current status of trial NCT06158841?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2024-05-19. Estimated completion is 2027-12.
What conditions does trial NCT06158841 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06158841?
The interventions under investigation include: Selinexor (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG), Elotuzumab (DRUG), Etentamig (DRUG).
Who is sponsoring clinical trial NCT06158841?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06158841 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.